These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 35489270)

  • 1. Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation.
    Reda Aouad M; Almehmadi MA; Faleh Albelwi F; Teleb M; Tageldin GN; Abu-Serie MM; Hagar M; Rezki N
    Bioorg Chem; 2022 Jul; 124():105816. PubMed ID: 35489270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing the Anticancer Potential of Targeting Tumor-Associated Metalloenzymes via VEGFR Inhibition by New Triazolo[4,3-
    Abd Al Moaty MN; El Ashry ESH; Awad LF; Ibrahim NA; Abu-Serie MM; Barakat A; Altowyan MS; Teleb M
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Halting Tumor Progression via Novel Non-Hydroxamate Triazole-Based Mannich Bases MMP-2/9 Inhibitors; Design, Microwave-Assisted Synthesis, and Biological Evaluation.
    Albelwi FF; Teleb M; Abu-Serie MM; Moaty MNAA; Alsubaie MS; Zakaria MA; El Kilany Y; Aouad MR; Hagar M; Rezki N
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA
    Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenging the anticolorectal cancer capacity of quinoxaline-based scaffold via triazole ligation unveiled new efficient dual VEGFR-2/MAO-B inhibitors.
    Ayoup MS; Ammar A; Abdel-Hamid H; Amer A; Abu-Serie MM; Nasr SA; Ghareeb DA; Teleb M; Tageldin GN
    Bioorg Chem; 2024 Feb; 143():107102. PubMed ID: 38211551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition,
    Othman DIA; Hamdi A; Tawfik SS; Elgazar AA; Mostafa AS
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166037. PubMed ID: 36651111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
    Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
    Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phthalazone tethered 1,2,3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities.
    Abdelgawad MA; Bukhari SNA; Musa A; Elmowafy M; Nayl AA; El-Ghorab AH; Sadek Abdel-Bakky M; Omar HA; Hadal Alotaibi N; Hassan HM; Ghoneim MM; Bakr RB
    Bioorg Chem; 2023 Apr; 133():106404. PubMed ID: 36812829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the dual-tail approach for the design and synthesis of novel Thiopyrimidine-Benzenesulfonamide hybrids as selective carbonic anhydrase inhibitors.
    Abdel-Mohsen HT; El Kerdawy AM; Omar MA; Petreni A; Allam RM; El Diwani HI; Supuran CT
    Eur J Med Chem; 2022 Jan; 228():114004. PubMed ID: 34847409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
    Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
    Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation.
    Rizk OH; Teleb M; Abu-Serie MM; Shaaban OG
    Bioorg Chem; 2019 Nov; 92():103189. PubMed ID: 31473473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.
    Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Elkaeed EB; Alsfouk BA; Alesawy MS; Husein DZ; Metwaly AM; Eissa IH
    PLoS One; 2022; 17(9):e0272362. PubMed ID: 36149902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unravelling the anticancer potency of 1,2,4-triazole-N-arylamide hybrids through inhibition of STAT3: synthesis and in silico mechanistic studies.
    Turky A; Bayoumi AH; Sherbiny FF; El-Adl K; Abulkhair HS
    Mol Divers; 2021 Feb; 25(1):403-420. PubMed ID: 32830299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.
    Abdallah AE; Mabrouk RR; Elnagar MR; Farrag AM; Kalaba MH; Sharaf MH; El-Fakharany EM; Bakhotmah DA; Elkaeed EB; Al Ward MMS
    Drug Des Devel Ther; 2022; 16():587-606. PubMed ID: 35281317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.